Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
Abstract The combination of immune checkpoint inhibitors (ICIs), such as ipilimumab and nivolumab, has revolutionized cancer treatment, particularly for advanced melanoma and other solid tumors. However, rare adverse events (AEs) associated with this combination are often underreported in clinical t...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Portfolio
2025-07-01
|
| Col·lecció: | Scientific Reports |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1038/s41598-025-07287-w |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|